表紙
市場調査レポート

医薬品新興国市場 (Pharmerging) の動向:2016〜2020年

Pharmerging Markets 2016-2020

発行 TechNavio (Infiniti Research Ltd.) 商品コード 345862
出版日 ページ情報 英文 104 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
医薬品新興国市場 (Pharmerging) の動向:2016〜2020年 Pharmerging Markets 2016-2020
出版日: 2015年11月25日 ページ情報: 英文 104 Pages
概要

新興国の医薬品市場は2016〜2020年にかけて、13%の年平均成長率 (CAGR) で成長する、と推計されています。新興国で公的・民間健康保険制度が整備され、一般市民の医薬品へのアクセスが改善されると共に、また公営・民間・多国籍企業と保険企業が連携して、福利厚生の一部として医療保険体制を構築していることが、市場成長の大きな要因となっています。また、各国のマクロ経済成長や所得増大、政府の支援プログラムの整備や医療費支出拡大も、市場成長を促しています。他方、市場は細分化が進んでおり、新製品上市・技術開発・企業合併・買収 (M&A) に伴って市場競争は更に激化していくものと思われます。

当レポートでは、医薬品新興国市場 (Pharmerging) の現状と将来展望について分析し、市場の概要や構造、市場規模の動向 (今後5年間の予測値)、地域グループ別 - ティアI (中国)・ティアII (ブラジル・インド・ロシア)・ティアIII (ポーランド・アルゼンチン・トルコ・メキシコ・ベネズエラ・ルーマニア・サウジアラビア・コロンビア・ベトナム・南アフリカ・アルジェリア・タイ・インドネシア・エジプト・パキスタン・ナイジェリア・ウクライナ) - の詳細動向、市場の促進・抑制要因とその影響力、主要企業のプロファイル、今後の市場機会などを調査・推計しております。

第1章 エグゼクティブ・サマリー

  • 分析結果の概略

第2章 分析範囲

  • 分析概要

第3章 市場分析の手法

  • 分析手法
  • 経済指標

第4章 イントロダクション

  • 市場動向の概略

第5章 世界の医薬品市場

  • 市場規模とその予測

第6章 医薬品新興国 (Pharmerging) 市場

第7章 市場環境

  • 市場規模とその予測
  • ファイブフォース分析

第8章 地域別の市場区分

第9章 ティアI諸国の市場の概要

  • 中国

第10章 ティアII諸国の市場の概要

  • ブラジル
  • ロシア
  • インド

第11章 ティアIII諸国の市場の概要

  • 市場規模とその予測

第12章 市場促進要因

  • 公的・私的健康保険
  • 医療費支出の増大
  • 各種疾患の発症率の上昇
  • 成熟市場における「特許の崖」 (パテントクリフ) の影響度

第13章 促進要因の影響力

第14章 市場の課題

  • 購入能力と市場へのアクセス
  • 激しい市場競争
  • 不完全な規制政策
  • 価格圧力

第15章 促進要因・課題の影響力

第16章 市場の動向

  • 戦略的な事業提携
  • ジェネリック医薬品の売上高増大
  • 企業合併・買収 (M&A)
  • 医薬品新興国市場での早期の製品上市

第17章 ベンダー環境

  • 競争シナリオ
  • AstraZeneca
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Sanofi
  • その他の有力ベンダー

第18章 付録

  • 略語集

第19章 Technavioについて

図表一覧

目次
Product Code: IRTNTR7935

Market outlook of the pharmerging markets

Technavios research analyst predicts the pharmerging markets to grow steadily at a CAGR of 13% during the forecast period. The increase in public and private healthcare insurance is the primary growth driver for this market. The governments of various pharmerging countries such as India have implemented several schemes that can be availed by patients to obtain free treatment for different diseases. Also, public and private multinational firms in collaboration with various insurance companies are providing healthcare coverage to their employees as a part of the employee welfare scheme, which is further leveraging people to seek treatment for the existing diseases.

The increase in healthcare spending by governments of pharmerging countries are expected to boost the market growth during the forecast period. Governments and pharmaceutical companies in these regions are making huge investments to improve accessibility to healthcare services, which is primarily driven by rising incomes, macroeconomic expansion, and government-supported policies and programs.

Segmentation and analysis of the pharmerging markets

  • Tier I countries (China)
  • Tier II countries (Brazil, India, and Russia)
  • Tier III countries (Poland, Argentina, Turkey, Mexico, Venezuela, Romania, Saudi Arabia, Colombia, Vietnam, South Africa, Algeria, Thailand, Indonesia, Egypt, Pakistan, Nigeria, and Ukraine)

The Tier I region (China) dominated the market during 2015, with a market share of 45%. An ageing population, increase in healthcare spending, and rise in market opportunities in suburban and rural areas are the main factors fueling the growth of the market in China.

Competitive landscape and key vendors

The pharmerging markets are highly fragmented due to the presence of numerous small and large vendors. Most of the international pharmaceutical companies are facing challenges such as price pressure, regulatory constraints, and competition from local and other international pharmaceutical companies in the pharmerging markets. The competitive environment in the market is expected to intensify with an increase in product extensions, technological innovations, and increase in mergers and acquisitions.

The leading vendors in the market are -

  • AstraZeneca
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Sanofi

Other prominent vendors in the market include Abbott Laboratories, AbbVie, Alexion Pharmaceuticals, Allergan, Amgen, Aspen, Astellas Pharma, Baxter, Bayer, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Chugai Pharmaceutical, CSL Behring, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Endo Health Pharmaceuticals, F. Hoffmann-La Roche, Fresenius, Gilead, Grifols, H. Lundbeck, Hospira, Johnson & Johnson, Kyowa Hakko Kirin, Mallinckrodt Pharmaceuticals, Menarini, Mitsubishi Tanabe Pharma, Mylan, Novo Nordisk, Otsuka, Shire, STADA Arzneimittel, Sun Pharmaceutical, Takeda Pharma, Teva Pharmaceutical, UCB, and Valeant Pharmaceuticals.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2020
  • What are the key factors driving the pharmerging markets
  • What are the key market trends impacting the growth of the pharmerging markets
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the vendors in the pharmerging markets
  • Trending factors influencing the market shares of Tier I, Tier II, and Tier III countries
  • What are the key outcomes of the five forces analysis of the pharmerging markets

Technavio also offers customization on reports based on specific client requirement.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Global pharmaceuticals market

  • Market size and forecast

PART 06: Pharmerging markets

PART 07: Market landscape

  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation based on geography

PART 09: Market overview of Tier I countries

  • China

PART 10: Market overview of Tier II countries

  • Brazil
  • Russia
  • India

PART 11: Market overview of Tier III countries

  • Market size and forecast

PART 12: Market drivers

  • Social and private health insurance
  • Increase in healthcare spending
  • High incidence of diseases
  • Impact of patent cliff on mature markets

PART 13: Impact of drivers

PART 14: Market challenges

  • Affordability and access
  • High competition
  • Partial regulatory policies
  • Price pressure

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Strategic alliances
  • Increase in generic sales
  • Mergers and acquisitions
  • Early drug launches in pharmerging markets

PART 17: Vendor landscape

  • Competitive scenario
  • AstraZeneca
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Sanofi
  • Other prominent vendors

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Global pharmaceuticals market 2015-2020 ($ billions)
  • Exhibit 02: Drivers, challenges, and trends in global pharmaceuticals market
  • Exhibit 03: Share of pharmerging markets in global pharmaceuticals market 2015
  • Exhibit 04: Pharmerging markets 2015-2020 ($ billions)
  • Exhibit 05: Shares of pharmerging markets in global pharmaceuticals market 2015-2020
  • Exhibit 06: Shares of Tier I, II, and III countries in pharmerging markets 2015-2020
  • Exhibit 07: Pharmerging market shares by country 2015
  • Exhibit 08: Shares of pharmerging markets in global pharmaceuticals market 2015 and 2020
  • Exhibit 09: Five forces analysis
  • Exhibit 10: Pharmerging markets by geography
  • Exhibit 11: Tier I: Geographical representation
  • Exhibit 12: Major therapy areas by drug sales 2015
  • Exhibit 13: Pharmaceuticals market in China 2015-2020 ($ billions)
  • Exhibit 14: Pharmaceuticals market in China: SWOT analysis
  • Exhibit 15: Geographic representation of Tier II countries
  • Exhibit 16: Pharmaceuticals market in Tier II countries 2015-2020 ($ billions)
  • Exhibit 17: Pharmaceuticals market in Brazil 2015-2020 ($ billions)
  • Exhibit 18: Pharmaceuticals market in Brazil: SWOT analysis
  • Exhibit 19: Pharmaceuticals market in Russia 2015-2020 ($ billions)
  • Exhibit 20: Pharmaceuticals market in Russia: SWOT analysis
  • Exhibit 21: Major therapy areas by drug sales 2015
  • Exhibit 22: Major acquisitions in pharmaceuticals sector in India
  • Exhibit 23: Pharmaceuticals market in India 2015-2020 ($ billions)
  • Exhibit 24: Pharmaceuticals market in India: SWOT analysis
  • Exhibit 25: Geographic representation of Tier III countries
  • Exhibit 26: Pharmaceuticals market in Tier III countries 2015-2020 ($ billions)
  • Exhibit 27: Revenue for select Tier III countries 2015 ($ billions)
  • Exhibit 28: Tier III countries' pharmaceuticals market: SWOT analysis
  • Exhibit 29: Impact of drivers
  • Exhibit 30: Impact of drivers and challenges
  • Exhibit 31: AstraZeneca: Business segmentation based on revenue 2014
  • Exhibit 32: AstraZeneca: Business segmentation based on revenue 2013 and 2014 ($ billions)
  • Exhibit 33: AstraZeneca: Geographical segmentation based on revenue 2014
  • Exhibit 34: AstraZeneca: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
  • Exhibit 35: AstraZeneca: SWOT analysis
  • Exhibit 36: GlaxoSmithKline: Business segmentation based on revenue 2014
  • Exhibit 37: GlaxoSmithKline: Business segmentation based on revenue 2013 and 2014 ($ billions)
  • Exhibit 38: GlaxoSmithKline: Geographical segmentation based on revenue 2014
  • Exhibit 39: GlaxoSmithKline: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
  • Exhibit 40: GlaxoSmithKline: SWOT analysis
  • Exhibit 41: Merck: Business segmentation based on revenue 2014
  • Exhibit 42: Merck: Business segmentation based on revenue 2013 and 2014 ($ billions)
  • Exhibit 43: Merck: Geographical segmentation based on revenue 2014
  • Exhibit 44: Merck: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
  • Exhibit 45: Merck: SWOT analysis
  • Exhibit 46: Novartis: Business segmentation based on revenue 2014
  • Exhibit 47: Novartis: Business segmentation based on revenue 2013 and 2014 ($ billions)
  • Exhibit 48: Novartis: Geographical segmentation based on revenue 2014
  • Exhibit 49: Novartis: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ millions)
  • Exhibit 50: Novartis :SWOT analysis
  • Exhibit 51: Pfizer: Business segmentation based on revenue 2014
  • Exhibit 52: Pfizer: Business segmentation based on revenue 2013 and 2014 ($ billions)
  • Exhibit 53: Pfizer: Geographical segmentation based on revenue 2014
  • Exhibit 54: Pfizer: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
  • Exhibit 55: Pfizer: SWOT analysis
  • Exhibit 56: Sanofi: Business segmentation based on revenue 2014
  • Exhibit 57: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
  • Exhibit 58: Sanofi: Geographical segmentation based on revenue 2014
  • Exhibit 59: Sanofi: YoY growth and revenue generated from sales of pharmaceutical products 2011-2014 ($ billions)
  • Exhibit 60: Sanofi: SWOT analysis
Back to Top